Observations on the intraperitoneal distribution of chromic phosphate (32P) suspension for intraperitoneal therapy.

Abstract

Seven patients received intraperitoneal chromic phosphate (32P) suspension in a 3-ml bolus with a saline flush, and another ten patients were given the suspension in a 500-ml infusion of normal saline. During the first six hours after administration, most 32P activity redistributed to the gravity-dependent portion of the peritoneal cavity. From 24 hours up to seven weeks after administration, activity distributions were fixed. Dispersions were heterogeneous in every patient, but the most marked examples of localized activity occurred in patients who had received bolus injections. We concluded that large-volume infusions and frequent changes in patient position for several hours following the infusion, contribute to improved dispersion of 32P suspension.

Efficacy and safety of 32P-nanocolloid for treatment of distant lymph node metastasis in VX2 tumor-bearing rabbits

“…Chromic 32 P colloid ( 32 P-nanocolloid) has been proposed to fulfi ll the requirements for such a radiation source [9,10]. Accordingly treatment of ovarian carcinoma [11][12][13], hepatocellular carcinoma [14], malignant pleural effusion and ascites [15,16], malignant peritoneal mesothelioma [17], refractory head and neck cancers [18], and pancreatic cancers [19,20] with internally administered 32 P-nanocolloid is associated with favorable clinical effi cacies and minimal side effects. Lord [21], who used 32 P-nanocolloid for direct endolymphatic irradiation of rabbit lymph nodes containing VX2 carcinoma cells, observed an initial rapid necrosis of all carcinoma cells within the physical range of isotope and subsequent fi brosis.…”